US equities |
NVDA $240.21 ▲+0.55% SPCX $171.74 ▲+0.38% MU $1,058.74 ▼-0.49% MRVL $286.72 ▲+5.70% AMD $653.58 ▲+3.46% INTC $114.23 ▼-1.68% AVGO $378.48 ▲+4.41% TSLA $380.17 ▲+0.38%
FinancialContent

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

11.59 -0.90 (-7.21%)
Delayed Quote Updated: 2:37 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab in patients with 1L NSCLC with EGFR exon 20 insertion mutations expected to initiate in Q1 2025, with initial data in mid-2026 
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
News headline image
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Stock Earnings: ORIC Pharmaceuticals Misses EPS for Q2 2024 ↗
ORIC stock results show that ORIC Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 ↗
ORIC stock results show that ORIC Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. 
Via Benzinga
News headline image
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >